Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the transaction, the chief financial officer now owns 19,738 shares of the company’s stock, valued at $151,587.84. This represents a 33.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zynex Trading Down 1.4 %

ZYXI stock traded down $0.11 during mid-day trading on Monday, reaching $7.73. 68,172 shares of the stock traded hands, compared to its average volume of 59,099. The business has a 50-day moving average price of $8.11 and a two-hundred day moving average price of $8.20. The stock has a market capitalization of $246.20 million, a PE ratio of 51.53 and a beta of 0.54. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex, Inc. has a one year low of $7.15 and a one year high of $13.77.

Institutional Trading of Zynex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in shares of Zynex by 66.5% during the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after buying an additional 118,615 shares during the last quarter. Barclays PLC increased its stake in Zynex by 43.3% in the third quarter. Barclays PLC now owns 28,821 shares of the company’s stock worth $236,000 after purchasing an additional 8,713 shares during the period. Jane Street Group LLC lifted its position in shares of Zynex by 8.9% during the third quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Zynex by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock valued at $334,000 after buying an additional 1,318 shares during the period. Finally, Quest Partners LLC boosted its holdings in shares of Zynex by 131.3% in the third quarter. Quest Partners LLC now owns 29,898 shares of the company’s stock valued at $244,000 after purchasing an additional 16,972 shares during the period. 29.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ZYXI shares. Royal Bank of Canada lowered their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Zynex in a research report on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.